SARS-CoV-2 Infection and the Liver

Area of Science:

• Virology
• Hepatology
• Immunology

Background:

• The emergence of SARS-CoV-2 in late 2019 presented with diverse symptoms, including respiratory distress.
• SARS-CoV-2 utilizes ACE2 receptors for cell entry, which are present in both respiratory tract and liver cells (cholangiocytes).
• The potential for direct liver injury in COVID-19 patients remains a significant question.

Purpose of the Study:

• To explore the possibility of direct liver injury caused by SARS-CoV-2.
• To discuss the multifactorial nature of liver derangements observed in some COVID-19 patients.
• To highlight the need for vaccine development and address safety concerns.

Main Methods:

• Review of existing evidence on SARS-CoV-2 cell entry mechanisms.
• Analysis of reported liver enzyme and function test abnormalities in COVID-19 patients.
• Consideration of potential causes for liver injury, including viral damage, drug toxicity, hypoxia, and microthromboses.

Main Results:

• ACE2 receptors, targeted by SARS-CoV-2, are found in cholangiocytes, suggesting potential direct liver involvement.
• Observed derangements in liver tests in some patients may stem from various causes, not solely direct viral attack.
• The multifactorial nature of liver injury necessitates careful management of COVID-19 patients with pre-existing liver conditions.

Conclusions:

• Liver injury in SARS-CoV-2 infection is likely multifactorial, involving direct viral effects, drug-induced injury, hypoxia, or microthromboses.
• Management strategies for COVID-19 patients with liver disease require careful consideration.
• Development of safe and effective vaccines is crucial for controlling SARS-CoV-2 spread and achieving population immunity, with attention to RNA- and DNA-based vaccine safety.